Professor of Pediatrics, UCSF
Hematology
Dr. Katherine K. Matthay, MD
|
|
Give Review
Dr. Katherine K. Matthay is an expert in the field of Hematology. She attended Perelman School of Medicine at the University of Pennsylvania. She received 3 awards: "America's Top Doctors", "America's Top Doctors for Cancer" and "Super Doctor". Katherine Matthay is also a published doctor. She has 99 paper published. The most recent paper is: Identification of patient subgroups with markedly disparate rates of MYCN amplification in neuroblastoma: A report from the International Neuroblastoma Risk Group proj...
Publications
- Different outcomes for relapsed versus refractory neuroblastoma after therapy with (131)I-metaiodobenzylguanidine ((131)I-MIBG).
- Evaluation and Outcome of Central Nervous System Involvement in Pediatric Acute Lymphoblastic Leukemia in Dar es Salaam, Tanzania.
- Extended Sedation With Continuous Midazolam or Dexmedetomidine Infusion for Young Children Receiving (131) I-MIBG Radiopharmaceutical Therapy for Advanced Neuroblastoma.
- Impact of Whole-Body Radiation Dose on Response and Toxicity in Patients With Neuroblastoma After Therapy With (131) I-Metaiodobenzylguanidine (MIBG).
- (131)I-Metaiodobenzylguanidine with Intensive Chemotherapy and Autologous Stem Cell Transplantation for High-Risk Neuroblastoma. A New Approaches to Neuroblastoma Ther...
- SIOP-PODC adapted risk stratification and treatment guidelines: Recommendations for neuroblastoma in low- and middle-income settings.
- Phase I/II study of (131)I-MIBG with vincristine and 5 days of irinotecan for advanced neuroblastoma.
- Reply to N.-K.V. Cheung et al.
- Drugging MYCN through an Allosteric Transition in Aurora Kinase A.
- Clinical, Biologic, and Prognostic Differences on the Basis of Primary Tumor Site in Neuroblastoma: A Report From the International Neuroblastoma Risk Group Project.
- Pediatric Cancer type predicts infection rate, need for critical care intervention, and mortality in the pediatric intensive care unit.
- Significance of clinical and biologic features in Stage 3 neuroblastoma: A report from the International Neuroblastoma Risk Group project.
- Likelihood of Bone Recurrence in Prior Sites of Metastasis in Patients With High-Risk Neuroblastoma.
- Neuroblastoma in older children, adolescents and young adults: A report from the international neuroblastoma risk group project.
- Current treatment and outcome for childhood Acute leukemia in Tanzania.
- Purged versus non-purged peripheral blood stem-Cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial.
- Adverse impact of regional lymph node involvement in Osteosarcoma.
- Phase I trial of fenretinide delivered orally in a novel organized lipid complex in patients with relapsed/refractory neuroblastoma: A report from the new approaches t...
- Acute Changes in Blood Pressure in Patients With Neuroblastoma Treated With (131) I-Metaiodobenzylguanidine (MIBG).
- 131I-Metaiodobenzylguanidine therapy in children with advanced neuroblastoma.
- Poly (ADP-Ribose) Polymerase Inhibitor MK-4827 together with Radiation as a Novel Therapy for Metastatic Neuroblastoma.
- Relevance of historical therapeutic approaches to the contemporary treatment of pediatric solid tumors.
- Infections in hospitalized children and young adults with Acute leukemia in Morocco.
- Semiquantitative mIBG Scoring as a Prognostic Indicator in Patients with Stage 4 Neuroblastoma: A Report from the Children's Oncology Group.
- Characteristics and outcomes of patients with Ewing Sarcoma over 40 years of age at diagnosis.
- Targeted isotretinoin in neuroblastoma: kinetics, genetics, or absorption.
- Tumor Dosimetry Using (124)Im-iodobenzylguanidine MicroPET/CT for (131)Im-iodobenzylguanidine Treatment of Neuroblastoma in a Murine Xenograft Model.
- 131I-MIBG followed by consolidation with busulfan, melphalan and autologous stem Cell transplantation for refractory neuroblastoma.
- Clinical Significance of Tumor-Associated Inflammatory Cells in Metastatic Neuroblastoma.
- Dose Escalation Study of No-Carrier-Added 131I-Metaiodobenzylguanidine for Relapsed or Refractory Neuroblastoma: New Approaches to Neuroblastoma Therapy Consortium Trial.
- Evaluation of plasma annexin V levels in children and young adults with solid tumors.
- Proteinuria in Metastatic Pheochromocytoma is Associated with an Increased Risk of Acute Respiratory Distress Syndrome, Spontaneously or After Therapy with 131I-Meta-i...
- Promising therapeutic targets in neuroblastoma.
- The significance of serial histopathology in a residual mass for outcome of intermediate risk stage 3 neuroblastoma.
- Paracrine Signaling Through MYCN Enhances Tumor-Vascular Interactions in Neuroblastoma.
- Predictors of Acute chemotherapy-associated toxicity in patients with Ewing sarcoma.
- Characteristics and outcome of patients with ganglioneuroblastoma, nodular subtype: A report from the INRG project.
- Pilot Induction Regimen Incorporating Pharmacokinetically Guided Topotecan for Treatment of Newly Diagnosed High-Risk Neuroblastoma: A Children's Oncology Group Study.
- Prognostic Value of the Stage 4S Metastatic Pattern and Tumor Biology in Patients With Metastatic Neuroblastoma Diagnosed Between Birth and 18 Months of Age.
- Symptom Cluster Analyses Based on Symptom Occurrence and Severity Ratings Among Pediatric Oncology Patients During Myelosuppressive Chemotherapy.
- A phase I study of zoledronic acid and low-dose cyclophosphamide in recurrent/refractory neuroblastoma: A new approaches to neuroblastoma therapy (NANT) study.
- Evaluation of polymorphisms in EWSR1 and risk of Ewing sarcoma: A report from the childhood Cancer survivor study.
- Clinical and Biologic Features Predictive of Survival After Relapse of Neuroblastoma: A Report From the International Neuroblastoma Risk Group Project.
- Clinical features and outcomes in patients with extraskeletal ewing Sarcoma.
- Comparison of (123) I-metaiodobenzylguanidine (MIBG) and (131) I-MIBG semi-quantitative scores in predicting survival in patients with stage 4 neuroblastoma: A report ...
- Guidelines for Imaging and Staging of Neuroblastic Tumors: Consensus Report from the International Neuroblastoma Risk Group Project.
- Vorinostat increases expression of functional norepinephrine transporter in neuroblastoma in vitro and in vivo model Systems.
- Response, survival, and toxicity after iodine-131-metaiodobenzylguanidine therapy for neuroblastoma in preadolescents, adolescents, and adults.
- Racial differences in the incidence of mesenchymal tumors associated with EWSR1 translocation.
- Phase I trial of lestaurtinib for children with refractory neuroblastoma: a new approaches to neuroblastoma therapy consortium study.
- Thyroid and hepatic function after high-dose 131 I-metaiodobenzylguanidine (131 I-MIBG) therapy for neuroblastoma.
- Changes in children's reports of symptom occurrence and severity during a course of myelosuppressive chemotherapy.
- Radiation dose estimation using preclinical imaging with 124I-metaiodobenzylguanidine (MIBG) PET.
- Phase II randomized comparison of topotecan plus cyclophosphamide versus topotecan alone in children with recurrent or refractory neuroblastoma: a Children's Oncology ...
- Osteosarcoma in children 5 years of age or younger at initial diagnosis.
- Peripheral blood stem Cell support for multiple cycles of dose intensive induction therapy is feasible with little risk of tumor contamination in advanced stage neurob...
- Ethnic and racial differences in patients with Ewing Sarcoma.
- Flow cytometric detection of Ewing sarcoma Cells in peripheral blood and bone marrow.
- Increasing incidence of neuroblastoma and potentially higher associated mortality of children from nonmetropolitan areas: analysis of the surveillance, epidemiology, a...
- Comparison of iodine-123 metaiodobenzylguanidine (MIBG) scan and [18F]fluorodeoxyglucose positron emission tomography to evaluate response after iodine-131 MIBG therap...
- Neuroblastoma: biology and staging.
- Clinicopathological characteristics of ganglioneuroma and ganglioneuroblastoma: a report from the CCG and COG.
- Successful treatment of high risk and recurrent pediatric desmoids using radiation as a component of multimodality therapy.
- Phase II study of high-dose [131I]metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma.
- Phase I trial of oral irinotecan and temozolomide for children with relapsed high-risk neuroblastoma: a new approach to neuroblastoma therapy consortium study.
- Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncol...
- Iodine-131--metaiodobenzylguanidine double infusion with autologous stem-Cell rescue for neuroblastoma: a new approaches to neuroblastoma therapy phase I study.
- Significance of MYCN amplification in international neuroblastoma staging System stage 1 and 2 neuroblastoma: a report from the International Neuroblastoma Risk Group ...
- The International Neuroblastoma Risk Group (INRG) classification System: an INRG Task Force report.
- Phase I study of ch14.18 with granulocyte-macrophage colony-stimulating factor and interleukin-2 in children with neuroblastoma after autologous bone marrow transplant...
- Lung metastases in neuroblastoma at initial diagnosis: A report from the International Neuroblastoma Risk Group (INRG) project.
- Nordihydroguaiaretic acid inhibits insulin-like growth factor signaling, growth, and survival in human neuroblastoma Cells.
- Long-term outcome and toxicities of intraoperative radiotherapy for high-risk neuroblastoma.
- A phase 2 trial of all-trans-retinoic acid in combination with interferon-alpha2a in children with recurrent neuroblastoma or Wilms tumor: A Pediatric Oncology Branch,...
- Phase II study on the effect of Disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma.
- Evaluation of semi-quantitative scoring System for metaiodobenzylguanidine (mIBG) scans in patients with relapsed neuroblastoma.
- Inhibition of phosphatidylinositol 3-kinase destabilizes Mycn protein and blocks malignant progression in neuroblastoma.
- Malignant pheochromocytomas and paraganGliomas: a phase II study of therapy with high-dose 131I-metaiodobenzylguanidine (131I-MIBG).
- Integrative genomics identifies distinct molecular classes of neuroblastoma and shows that multiple genes are targeted by regional alterations in DNA copy number.
- Is liver metastasis in neuroblastoma an indication for treatment reduction?
- Phase I dose escalation of iodine-131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-Cell transplantation in refractory neuroblastoma: a n...
- Favorable prognosis for patients 12 to 18 months of age with stage 4 nonamplified MYCN neuroblastoma: a Children's Cancer Group Study.
- Tumor response and toxicity with multiple infusions of high dose 131I-MIBG for refractory neuroblastoma.
- EnLarged and prominent nucleoli may be indicative of MYCN amplification: a study of neuroblastoma (Schwannian stroma-poor), undifferentiated/poorly differentiated subt...
- TrkA expression in peripheral neuroblastic tumors: prognostic significance and biological relevance.
- Hematologic toxicity of high-dose iodine-131-metaiodobenzylguanidine therapy for advanced neuroblastoma.
- Efficacy of complete resection for high-risk neuroblastoma: a Children's Cancer Group study.
- Revision of the International Neuroblastoma Pathology Classification: confirmation of favorable and unfavorable prognostic subsets in ganglioneuroblastoma, nodular.
- High-dose 131I-metaiodobenzylguanidine therapy for 12 patients with malignant pheochromocytoma.
- Secondary myelodysplastic syndrome and Leukemia following 131I-metaiodobenzylguanidine therapy for relapsed neuroblastoma.
- Central Nervous system metastases in neuroblastoma: radiologic, clinical, and biologic features in 23 patients.
- Correlation of early metastatic response by 123I-metaiodobenzylguanidine scintigraphy with overall response and event-free survival in stage IV neuroblastoma.
- Impact of radiotherapy for high-risk neuroblastoma: a Children's Cancer Group study.
- Pilot study of iodine-131-metaiodobenzylguanidine in combination with myeloablative chemotherapy and autologous stem-Cell support for the treatment of neuroblastoma.
- Symptom Assessment in Pediatric Oncology: How Should Concordance Between Children's and Parents' Reports Be Evaluated?
- Clinical Features and Outcomes Differ between Skeletal and Extraskeletal Osteosarcoma.
- Superselective intra-arterial melphalan therapy for newly diagnosed and refractory Retinoblastoma: results from a single institution.
- Identification of patient subgroups with markedly disparate rates of MYCN amplification in neuroblastoma: A report from the International Neuroblastoma Risk Group proj...
Schools
University Of Pennsylvania School Of Medicine
Colo
University Calif
Conditions Treated
- Acute Leukemia
- Adrenal Gland Cancer
- Anemia
- Brain and Nervous System Cancer (incl. Gliomas, Astrocytoma, Schwannoma, Medulloblastoma, Chordoma)
- View All
Doctors Specialties
- Hematology
Accepted Insurances
Awards
- America's Top Doctors
- America's Top Doctors for Cancer
- Super Doctor
Education
-
UCSF -
University of Colorado -
Perelman School of Medicine at the University of Pennsylvania
Hospital
-
John Muir Medical Center, Walnut Creek -
UCSF Medical Center
Helpful Reviews
Similar Doctors
|
|
Dr. Richard A. Bohannon, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Andrea L. Harzstark, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jeffrey M. Venstrom, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Rahul R. Aggarwal, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Richard J. Cohen, MD |
|
|
Dr. Dean Fong, DO
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Barbara G. Jensen, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Benjamin H. Kim, MD |
|
|
Dr. Robert L. Cohen, MD |